Production facilities
 |
The company has continuously invested in developing and improving its unique products and production processes. Biotec Pharmacon is now operating a modern, industrial manufacturing facility in accordance with GMP-requirements for pharmaceutical products. The plant has a production capacity that makes it possible to increase production significantly to meet the demands arising from the company's pharmaceutical plans, without further investments and increases in overhead.
News
- Svein Lien appointed new CEO of Biotec Pharmacon ASAMarch 10,2010Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen’s decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 15 March, 2010.
- Biotec Pharmacon presenting re-established platform at BIO-Europe 2010March 09,2010Dr Sven Rohmann presented on behalf of Biotec Pharmacon at BIO-Europe Spring 2010 in Barcelona. The presentation took place at March 9, 12:30, under the AutoImmune/Inflammation Section.
- Testing SBG packaging containers after weak results from oral mucositis study February 22,2010Biotec Pharmacon has received data showing that SBG failed to show superiority over placebo in the phase III study for oral mucositis. Newly available biological activity assays indicate that SBG used in the diabetic ulcer program may have been inactivated as a result of interaction with polyethylene in the product containers. The company plans to carry out accelerated stability studies of SBG with alternative containers.